Cargando…
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and r...
Autores principales: | Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine, Wind-Rotolo, Megan, Signoretti, Sabina, McDermott, David F., Freeman, Gordon J., Van Allen, Eliezer M., Schreiber, Stuart L., Stephen Hodi, F., Sellers, William R., Garraway, Levi A., Clish, Clary B., Choueiri, Toni K., Giannakis, Marios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761178/ https://www.ncbi.nlm.nih.gov/pubmed/31554815 http://dx.doi.org/10.1038/s41467-019-12361-9 |
Ejemplares similares
-
Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022) -
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017) -
Landscape of tumor-infiltrating T cell repertoire of human cancers
por: Li, Bo, et al.
Publicado: (2016) -
Discovery and Features of an Alkylating Signature in Colorectal Cancer
por: Gurjao, Carino, et al.
Publicado: (2021) -
RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition
por: Fang, Lishan, et al.
Publicado: (2022)